Summit Therapeutics Announces Completion Of Enrollment In Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC; FDA Grants Fast Track Designation For Ivonescimab In 2L+ EGFRm NSCLC

Benzinga16:19 ET

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

BenzingaOct 2 16:18 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaOct 2 08:05 ET

Enliven Therapeutics Analyst Ratings

BenzingaOct 1 11:49 ET · Ratings

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

BenzingaOct 1 11:40 ET

IGM Biosciences Analyst Ratings

BenzingaOct 1 09:12 ET · Ratings